Navigation Links
New Intra-Arrest Cooling Method May Save More Brains During Cardiac Arrest
Date:11/15/2009

ORLANDO, Fla., Nov. 15 /PRNewswire/ -- The first randomized intra-arrest cooling study performed using a novel intra-nasal cooling method showed much faster and earlier cooling in treated patients and significantly higher neurologically intact survival - to - discharge rate in many patients. The Pre-Resuscitation Intra-Nasal Cooling Effectiveness (PRINCE) study involved 200 patients and was conducted by 15 Emergency Medical Systems (EMS) in Belgium, Germany, Italy, Czech Republic and Sweden. The aim was to determine safety and efficacy of intra-nasal cooling during ongoing resuscitation of cardiac arrest patients even before the return of circulation (ROSC).

The study was conducted using RhinoChill(TM), a non-invasive nasal catheter that sprays a rapidly evaporating coolant liquid into the nasal cavity. This large cavity is a heat exchanger and lies right under the brain.

The trial was designed to determine the safety and effectiveness of early cooling initiated at the site of the arrest. The RhinoChill(TM) technology enabled cooling to start much earlier than is possible with conventional methods used in a hospital setting and focuses on the brain. "The brain is the organ that dies first so the closer to the time of arrest the brain is cooled, the more of it is rescued," said Denise Barbut, M.D, founder and CEO of BeneChill, the company that makes RhinoChill. "The brain is the organ that controls the heart, much like a puppet on a string," she added.

Additional endpoints included cooling rates, time to achieve target temperature, ease of use in the field, ROSC rates, survival and neurologically intact survival. EMS personnel recruited adults over 18 years old who were in cardiac arrest and not hospitalized during resuscitation. All patients who were deemed eligible for advance cardiac life support (ACLS) were included as long as the arrest was witnessed and cardiopulmonary resuscitation (CPR) was initiated within 20 minutes of collapse.

The results of the study included:

  • Cooling was initiated 23 minutes following arrest and lowered brain temperature (tympanic) (34.2 degrees C vs. 35.5 degrees C) and body (core) temperature (35.1 degrees C vs. 35.8 degrees C) significantly by ER arrival.
  • Time to target tympanic temperature of 34 degrees was three hours faster and time to target core temperature was two hours faster in patients cooled intra-nasally in the field compared to those receiving hospital cooling alone.
  • Survival to discharge was higher in treated patients admitted to hospital (46.7% vs 31%) and significantly higher in those in whom CPR was initiated within 10 minutes of collapse, irrespective of rhythm (59.1% vs 29.4%).
  • Neurologically intact survival to discharge was higher in treated patients admitted to the hospital (36.7% vs 21.4%) and significantly higher in those in whom CPR was initiated within 10 minutes of collapse, irrespective of rhythm (45.5% vs 17.6%).
  • Intra-nasal cooling with RhinoChill was feasible and safe during an arrest. Nasal discoloration was the most commonly reported adverse event occurring in 13 patients. This resolved spontaneously in all patients who were successfully resuscitated.

Maaret Castren, M.D, Ph.D of the Department of Clinical Science and Education, Karolinska Institute, Stockholm, Sweden and the Department of Emergency Medicine, Sodersjukhuset and PRINCE lead investigator noted, "In this study, early cooling of the brain combined with early CPR favorably affected outcomes, irrespective of rhythm. We believe that this study demonstrates that making every attempt to initiate both CPR and intra-arrest cooling as early as possible in the resuscitation process should be adopted."

The EMS teams also noted that the portability of the device and ease of use meant that cooling could be administered in the field by non-specialized medical personnel. This also is useful in the hospital setting where the patient can be transported around with on-going cooling.

Dr. Castren presented the findings in Orlando, FL on Sunday, November 15 during the American Heart Association's Resuscitation Science Symposium "Best of the Best" presentations.

The sponsor of the study is BeneChill, a privately held medical device company which develops novel, rapid cooling systems to improve survival and brain function after cardiac arrest and other forms of brain ischemia. Its lead product, RhinoChill, which was used in the PRINCE study, can be administered quickly and close to the brain using a nasal catheter that delivers a rapidly evaporating coolant. RhinoChill will be marketed in Europe in early 2010 and currently is not available in the US.

SOURCE BeneChill


'/>"/>
SOURCE BeneChill
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BeneChill Launches European Study of Intra-Arrest Cooling
2. Rapid Cooling Might Help Heart Attack Patients
3. Cooling May Reduce Brain Lesions in Newborns
4. Cooling Helps Oxygen-Deprived Newborns
5. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
6. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
7. Nationwide Heat Wave Finally Gives Way To Cooling Trend
8. Keep Safety in Mind While Cooling Off in the Water
9. Chill Cooling Towels Introduces Instant Relief for Hot Flashes and Night Sweats
10. St. Josephs Healthcare System Becomes First Hospital in the Region to Implement Pre-Hospital Therapeutic Cooling to Save the Lives of Cardiac Arrest Patients
11. Top Neurology Programs Control Fever with Arctic Sun Cooling Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: